Browse EVA1B

Summary
SymbolEVA1B
Nameeva-1 homolog B (C. elegans)
Aliases FLJ10647; C1orf78; FAM176B; chromosome 1 open reading frame 78; family with sequence similarity 176, member ......
Chromosomal Location1p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Single-pass membrane protein
Domain -
Function

-

> Gene Ontology
 
Biological Process -
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolEVA1B
Nameeva-1 homolog B (C. elegans)
Aliases FLJ10647; C1orf78; FAM176B; chromosome 1 open reading frame 78; family with sequence similarity 176, member ......
Chromosomal Location1p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between EVA1B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolEVA1B
Nameeva-1 homolog B (C. elegans)
Aliases FLJ10647; C1orf78; FAM176B; chromosome 1 open reading frame 78; family with sequence similarity 176, member ......
Chromosomal Location1p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of EVA1B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolEVA1B
Nameeva-1 homolog B (C. elegans)
Aliases FLJ10647; C1orf78; FAM176B; chromosome 1 open reading frame 78; family with sequence similarity 176, member ......
Chromosomal Location1p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of EVA1B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.1750.0275
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.5490.54
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.9090.647
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.4140.415
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.7010.719
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.050.983
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2310.549
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.7330.39
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2020.849
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2190.879
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.7820.701
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3280.0117
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolEVA1B
Nameeva-1 homolog B (C. elegans)
Aliases FLJ10647; C1orf78; FAM176B; chromosome 1 open reading frame 78; family with sequence similarity 176, member ......
Chromosomal Location1p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EVA1B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolEVA1B
Nameeva-1 homolog B (C. elegans)
Aliases FLJ10647; C1orf78; FAM176B; chromosome 1 open reading frame 78; family with sequence similarity 176, member ......
Chromosomal Location1p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EVA1B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EVA1B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolEVA1B
Nameeva-1 homolog B (C. elegans)
Aliases FLJ10647; C1orf78; FAM176B; chromosome 1 open reading frame 78; family with sequence similarity 176, member ......
Chromosomal Location1p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EVA1B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolEVA1B
Nameeva-1 homolog B (C. elegans)
Aliases FLJ10647; C1orf78; FAM176B; chromosome 1 open reading frame 78; family with sequence similarity 176, member ......
Chromosomal Location1p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of EVA1B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolEVA1B
Nameeva-1 homolog B (C. elegans)
Aliases FLJ10647; C1orf78; FAM176B; chromosome 1 open reading frame 78; family with sequence similarity 176, member ......
Chromosomal Location1p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between EVA1B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolEVA1B
Nameeva-1 homolog B (C. elegans)
Aliases FLJ10647; C1orf78; FAM176B; chromosome 1 open reading frame 78; family with sequence similarity 176, member ......
Chromosomal Location1p34.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting EVA1B collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.